Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akeso, Inc. (HK:9926) is conducting a Phase Ib/II clinical study titled ‘A Phase Ib/II Study of Anti-PD-1/LAG-3 Bispecific Antibody AK129 Combinations in Advanced Solid Tumors.’ The study aims to determine the recommended Phase II dose of AK129 combinations and assess their safety and efficacy in treating advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal adenocarcinoma.
The study tests AK129, a bispecific antibody, in combination with chemotherapy drugs like Pemetrexed, Paclitaxel, and Carboplatin. AK129 is designed to enhance the immune response against cancer cells.
This interventional study uses a randomized, parallel assignment model without masking and focuses on treatment. It aims to establish the effectiveness of AK129 in combination with other treatments.
The study began on April 6, 2025, with primary completion expected soon. The last update was on May 28, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
Positive results from this study could boost Akeso’s stock by enhancing its competitive position in the oncology market, potentially attracting investor interest. This is especially relevant given the competitive landscape in cancer immunotherapy.
The study is ongoing, with further details available on the ClinicalTrials portal.